Patrick Royston

List of Publications by Year in descending order

48 papers	15,627 citations	230014 27 h-index	223390 49 g-index
51 all docs	51 docs citations	51 times ranked	28339 citing authors

#	Article	IF	Citations
1	Multiple imputation using chained equations: Issues and guidance for practice. Statistics in Medicine, 2011, 30, 377-399.	0.8	6,168
2	Dichotomizing continuous predictors in multiple regression: a bad idea. Statistics in Medicine, 2006, 25, 127-141.	0.8	1,711
3	Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Statistics in Medicine, 2002, 21, 2175-2197.	0.8	1,062
4	Prognosis and prognostic research: what, why, and how?. BMJ: British Medical Journal, 2009, 338, b375-b375.	2.4	952
5	Prognosis and prognostic research: Developing a prognostic model. BMJ: British Medical Journal, 2009, 338, b604-b604.	2.4	906
6	Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Medical Research Methodology, 2013, 13, 152.	1.4	605
7	Further Development of Flexible Parametric Models for Survival Analysis. The Stata Journal, 2009, 9, 265-290.	0.9	590
8	The design of simulation studies in medical statistics. Statistics in Medicine, 2006, 25, 4279-4292.	0.8	529
9	A new measure of prognostic separation in survival data. Statistics in Medicine, 2004, 23, 723-748.	0.8	371
10	The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Statistics in Medicine, 2011, 30, 2409-2421.	0.8	363
11	Explained Variation for Survival Models. The Stata Journal, 2006, 6, 83-96.	0.9	238
12	A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Statistics in Medicine, 2004, 23, 2509-2525.	0.8	234
13	Reporting methods in studies developing prognostic models in cancer: a review. BMC Medicine, 2010, 8, 20.	2.3	160
14	Reconstructing Time-to-event Data from Published Kaplanâ€“Meier Curves. The Stata Journal, 2017, 17, 786-802.	0.9	157
15	Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet, The, 2010, 375, 641-648.	6.3	117
16	Simplifying a prognostic model: a simulation study based on clinical data. Statistics in Medicine, 2002, 21, 3803-3822.	0.8	107
17	Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer. Statistics in Medicine, 2004, 23, 907-926.	0.8	101
18	A simulation study of predictive ability measures in a survival model I: Explained variation measures. Statistics in Medicine, 2012, 31, 2627-2643.	0.8	72

#	Article	IF	Citations
19	Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards. BMJ: British Medical Journal, 2017, 357, j2250.	2.4	67
20	Metaâ€analysis of timeâ€toâ€event outcomes from randomized trials using restricted mean survival time: application to individual participant data. Statistics in Medicine, 2015, 34, 2881-2898.	0.8	51
21	Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated. BMC Medical Research Methodology, 2016, 16, 16.	1.4	51
22	Two Techniques for Investigating Interactions between Treatment and Continuous Covariates in Clinical Trials. The Stata Journal, 2009, 9, 230-251.	0.9	49
23	Visualizing Length of Survival in Time-to-Event Studies: A Complement to Kaplan Meier Plots. Journal of the National Cancer Institute, 2008, 100, 92-97.	3.0	36
24	Reconstructing time-to-event data from published Kaplan-Meier curves. The Stata Journal, 2017, 17, 786-802.	0.9	36
25	A Menu-driven Facility for Complex Sample Size Calculation in Randomized Controlled Trials with a Survival or a Binary Outcome: Update. The Stata Journal, 2005, 5, 123-129.	0.9	31
26	Interaction of treatment with a continuous variable: simulation study of significance level for several methods of analysis. Statistics in Medicine, 2013, 32, 3788-3803.	0.8	30
27	An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect. Trials, 2014, 15, 314.	0.7	29
28	Interaction of treatment with a continuous variable: simulation study of power for several methods of analysis. Statistics in Medicine, 2014, 33, 4695-4708.	0.8	26
29	Prognostic survival model for people diagnosed with invasive cutaneous melanoma. BMC Cancer, 2015, 15, 27.	1.1	22
30	Metaâ€analysis of nonâ€linear exposureâ€outcome relationships using individual participant data: A comparison of two methods. Statistics in Medicine, 2019, 38, 326-338.	0.8	22
31	Discrimination-based sample size calculations for multivariable prognostic models for time-to-event data. BMC Medical Research Methodology, 2015, 15, 82.	1.4	21
32	A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome. Trials, 2020, 21, 315.	0.7	21
33	Modelling to extract more information from clinical trials data: On some roles for the bootstrap. Statistics in Medicine, 2007, 26, 4989-5001.	0.8	18
34	Combined test versus logrank/Cox test in 50 randomised trials. Trials, 2019, 20, 172.	0.7	17
35	Estimating the Treatment Effect in a Clinical Trial Using Difference in Restricted Mean Survival Time. The Stata Journal, 2015, 15, 1098-1117.	0.9	15
36	Multivariable fractional polynomial interaction to investigate continuous effect modifiers in a meta-analysis on higher versus lower PEEP for patients with ARDS. BMJ Open, 2016, 6, e011148.	0.8	13

#	Article	IF	Citations
37	Tools to Simulate Realistic Censored Survival-Time Distributions. The Stata Journal, 2012, 12, 639-654.	0.9	11
38	A Combined Test for a Generalized Treatment Effect in Clinical Trials with a Time-to-event Outcome. The Stata Journal, 2017, 17, 405-421.	0.9	10
39	Mfpa: Extension of mfp Using the ACD Covariate Transformation for Enhanced Parametric Multivariable Modeling. The Stata Journal, 2016, 16, 72-87.	0.9	8
40	Power and sample-size analysis for the Roystonâ€“Parmar combined test in clinical trials with a time-to-event outcome. The Stata Journal, 2018, 18, 3-21.	0.9	7
41	Personalized Model to Predict Keratoconus Progression From Demographic, Topographic, and Genetic Data. American Journal of Ophthalmology, 2022, 240, 321-329.	1.7	7
42	A combined test for a generalized treatment effect in clinical trials with a time-to-event outcome. The Stata Journal, 2017, 17, 405-421.	0.9	5
43	Reconstructing Time-to-event Data from Published Kaplanâ€“Meier Curves. The Stata Journal, 2017, 17, 786-802.	0.9	4
44	mfpa: Extension of mfp using the ACD covariate transformation for enhanced parametric multivariable modeling. The Stata Journal, 2016, 16, 72-87.	0.9	4
45	A smooth covariate rank transformation for use in regression models with a sigmoid dose-response function. The Stata Journal, 2014, 14, 329-341.	0.9	3
46	Investigating treatment-effect modification by a continuous covariate in IPD meta-analysis: an approach using fractional polynomials. BMC Medical Research Methodology, 2022, 22, 98.	1.4	3
47	Power and Sample-Size Analysis for the Roystonâ€“Parmar Combined Test in Clinical Trials with a Time-to-Event Outcome: Correction and Program Update. The Stata Journal, 2018, 18, 995-996.	0.9	2
48	The extension of total gain (TG) statistic in survival models: properties and applications. BMC Medical Research Methodology, 2015, 15, 50.	1.4	1